Celltrion Inc (068270) - Cash Flow Conversion Efficiency

Latest as of March 2026: 0.013x

Based on the latest financial reports, Celltrion Inc (068270) has a cash flow conversion efficiency ratio of 0.013x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (₩238.15 Billion ≈ $161.39 Million USD) by net assets (₩17.81 Trillion ≈ $12.07 Billion USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see Celltrion Inc (068270) total market value for the company's overall valuation and market capitalisation.

Celltrion Inc - Cash Flow Conversion Efficiency Trend (2007–2025)

This chart illustrates how Celltrion Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data.

Celltrion Inc Competitors by Cash Flow Conversion Efficiency

The table below lists competitors of Celltrion Inc ranked by their cash flow conversion efficiency. Explore Celltrion Inc (068270) cash flow quality to measure how well operating cash flow supports reported net income.

Company Cash Flow Conversion Efficiency
ON Semiconductor Corporation
NASDAQ:ON
0.064x
MongoDB
NASDAQ:MDB
0.069x
Gulf Energy Development Public Company Limited
BK:GULF
0.021x
Nokia Oyj
HE:NOKIA
0.030x
China Hongqiao Group Ltd
F:H0Q
N/A
Orsted A/S
CO:ORSTED
0.074x
Guangdong Songfa Ceramics Co
SHG:603268
-0.060x
Hannover Rück SE
F:HNR1
0.128x

Annual Cash Flow Conversion Efficiency for Celltrion Inc (2007–2025)

The table below shows the annual cash flow conversion efficiency of Celltrion Inc from 2007 to 2025. View today's stock price for Celltrion Inc for real-time trading data and today's change.

Year Net Assets Operating Cash Flow Cash Flow Conversion Efficiency Change
2025-12-31 ₩17.35 Trillion
≈ $11.76 Billion
₩646.05 Billion
≈ $437.82 Million
0.037x -27.43%
2024-12-31 ₩17.58 Trillion
≈ $11.91 Billion
₩901.87 Billion
≈ $611.18 Million
0.051x +63.56%
2023-12-31 ₩17.13 Trillion
≈ $11.61 Billion
₩537.16 Billion
≈ $364.02 Million
0.031x +15424.89%
2022-12-31 ₩4.27 Trillion
≈ $2.90 Billion
₩863.53 Million
≈ $585.20K
0.000x -99.91%
2021-12-31 ₩4.05 Trillion
≈ $2.74 Billion
₩911.16 Billion
≈ $617.48 Million
0.225x +119.83%
2020-12-31 ₩3.43 Trillion
≈ $2.32 Billion
₩350.75 Billion
≈ $237.70 Million
0.102x -37.98%
2019-12-31 ₩2.87 Trillion
≈ $1.95 Billion
₩473.99 Billion
≈ $321.22 Million
0.165x +17.38%
2018-12-31 ₩2.60 Trillion
≈ $1.76 Billion
₩364.79 Billion
≈ $247.21 Million
0.141x -30.28%
2017-12-31 ₩2.41 Trillion
≈ $1.63 Billion
₩485.98 Billion
≈ $329.34 Million
0.202x +76.71%
2016-12-31 ₩2.20 Trillion
≈ $1.49 Billion
₩250.89 Billion
≈ $170.02 Million
0.114x +166.21%
2015-12-31 ₩1.81 Trillion
≈ $1.23 Billion
₩77.57 Billion
≈ $52.57 Million
0.043x -60.21%
2014-12-31 ₩1.35 Trillion
≈ $913.37 Million
₩145.16 Billion
≈ $98.37 Million
0.108x -14.59%
2013-12-31 ₩1.09 Trillion
≈ $736.73 Million
₩137.08 Billion
≈ $92.90 Million
0.126x +531.44%
2012-12-31 ₩1.05 Trillion
≈ $711.67 Million
₩20.97 Billion
≈ $14.21 Million
0.020x -71.38%
2011-12-31 ₩899.55 Billion
≈ $609.61 Million
₩62.76 Billion
≈ $42.53 Million
0.070x +61.96%
2010-12-31 ₩779.89 Billion
≈ $528.52 Million
₩33.60 Billion
≈ $22.77 Million
0.043x -72.63%
2009-12-31 ₩285.67 Billion
≈ $193.60 Million
₩44.95 Billion
≈ $30.46 Million
0.157x -26.10%
2008-12-31 ₩219.72 Billion
≈ $148.90 Million
₩46.79 Billion
≈ $31.71 Million
0.213x +117.06%
2007-12-31 ₩26.59 Billion
≈ $18.02 Million
₩2.61 Billion
≈ $1.77 Million
0.098x --

About Celltrion Inc

KO:068270 Korea Biotechnology
Market Cap
$28.95 Billion
₩42.72 Trillion KRW
Market Cap Rank
#931 Global
#17 in Korea
Share Price
₩186300.00
Change (1 day)
-0.96%
52-Week Range
₩159400.00 - ₩248500.00
All Time High
₩389079.95
About

Celltrion, Inc., a biopharmaceutical company, engages in the development, production, and sale of development, production, and sale of medicinal products. It offers biosimilars, including Remsima for rheumatoid arthritis and inflammatory bowel disease; Truxima for non-hodgkin's lymphoma and chronic lymphocytic leukemia; Herzuma for metastatic breast and gastric cancer; Remsima SC and Yuflyma for … Read more